Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.
Bronstein, Gewirtz & Grossman, LLC Encourages iRhythm Technologies, Inc. (IRTC) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.
Top 3 Robotics and Automation Stocks for the Next AI Boom
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.
iRhythm resumed with an Equal Weight at Wells Fargo
Wells Fargo analyst Nathan Treybeck resumed coverage of iRhythm with an Equal Weight rating and $86 price target. The analyst believes stock upside will be limited until there is greater certainty on resolving outstanding regulatory issues. Until there is a clean facility re-inspection and the current 483s and warning letter are lifted, there continues to be risk of additional 483s or the current 483s becoming another warning letter or a potential consent decree, the analyst tells investors in a research note.
iRhythm Technologies, Inc. (IRTC) Q3 2024 Earnings Call Transcript
iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q3 2024 Results Conference Call October 30, 2024 4:30 PM ET Company Participants Stephanie Zhadkevich - Director, Investor Relations Quentin Blackford - President and CEO Daniel Wilson - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Macauley Kilbane - William Blair Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG LLC David Ryman - Goldman Sachs David Rescott - Baird Richard Newitter - Truist William Plovanic - Canaccord Genuity Suraj Kalia - Oppenheimer Operator Hello, everyone, and welcome to iRhythm's Third Quarter 2024 Earnings Call. My name's Lydia, and I'll be your operator today.
IRhythm Technologies (IRTC) Reports Q3 Loss, Tops Revenue Estimates
IRhythm Technologies (IRTC) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.89 per share a year ago.
iRhythm Technologies (IRTC) Soars 21.7%: Is Further Upside Left in the Stock?
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says
On Monday, the FDA approved iRhythm Technologies, Inc.'s IRTC 510(k) submission related to prior design changes to the Zio AT device via letter to file.
